How bacteria develop resistance to antisense antibiotics – and how future therapies can be designed to reduce the risk of resistance

Antimicrobial resistance is one of the greatest challenges facing modern medicine. A new class of programmable antibiotics known as asobiotics can be used to treat bacterial infections when classical antibiotics fail. A team of researchers from TWINCORE, Centre for Experimental and Clinical Infection Research, the RESIST Cluster of Excellence and from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has now studied, how bacteria adapt to asobiotics. They recently published their finding in Nature Communications.